| Document |
Document Title |
|
JP2604842B2 |
The present invention involves improved processes for the dehalogenation of 9 alpha -halosteroids (I) (I) to produce the corresponding 11 beta -hydroxy steroids (II) (II) which are known to be useful as pharmaceutical, where the improvem...
|
|
JP2599606B2 |
A compound of the formula I wherein R1 is hydrogen or methyl, R2 is methyl or ethyl, the A,B,C and D rings optionally have one or more double bonds and are optionally substituted with one or more members of the group consisting of haloge...
|
|
JPH09501433A |
The applications discloses the treatment of inflammatory disorders, in particular those associated with rheumatoid, arthritis, gout, gouty arthritis and Behcet's syndrome, with 2-methoxyestradiol.
|
|
JPH0912593A |
To obtain the new derivatives comprising a specific 17- hydroxyiminoalkylcyclopentane perhydrophenanthrene derivative, etc., having affinity to Na+, K+-ATPase receptors, and useful for the therapy of cardiac failures, hypertension, etc. ...
|
|
JP2565746B2 |
NEW MATERIAL:A compound expressed by formula I [R<1> is COOR<11> (R<11> is H, 1-20C alkyl, etc.), CONR<13>R<14> (R<13> and R<14> are each H or 1-4C alkyl or together NR<13>R<14> which is amino acid residue, etc.), etc.; Tx is formula II ...
|
|
JP2550777B2 |
|
|
JP2549721B2 |
17 beta -Cyano-17 alpha -hydroxy steroids (I) are transformed to 17 alpha -halo silyl ethers (II) which are intermediates useful in the production of progesterones (V), 17-hydroxyprogesterones (VI), corticoids (VII) and 21-halo corticoid...
|
|
JP2549724B2 |
Amine salts of alkane-1,n-dicarboxylic acid mono-(2-sulfato-ethyl)amides of the formula (I): HOC(O)-(CH2)n-C(O)-N(R1)-CH2CH2SO3 <-> <+> HN(R2)3, wherein R1 is selected from the group consisting of hydrogen, C1-C8 alkyl and phenyl, R2 is ...
|
|
JP2545522B2 |
This invention provides novel tetrahydro steroids which are useful in inhibiting angiogenesis and have the following structure: A compound of the formula: wherein R1 is beta -CH3 or beta -CH2H5; wherein R2 is H, and R3 is =0, -OH, -0-alk...
|
|
JP2515967B2 |
PURPOSE: To obtain a new process for the preparation of corticoid and progesterone useful as pharmaceuticals by reacting a specific α-halo silyl ether with a non-nucleophilic base and then, reacting the resulting product with two specif...
|
|
JPH08169821A |
To provide a method for treating vascular leak syndrome by using an effective amount of a compound selected from the group consisting of a corticosteroid, a non-steroidal anti-inflammatory agent, a phospholipase A2 inhibitor and 15-deoxy...
|
|
JP2509467B2 |
PURPOSE: To obtain a novel compound good in crystallinity, useful as a starting material for producing strong active gestagen used for contraceptive regulators and capable of producing gestoden by one shot method in good yield. CONSTITUT...
|
|
JPH08505124A |
PCT No. PCT/FR93/01029 Sec. 371 Date Jun. 21, 1995 Sec. 102(e) Date Jun. 21, 1995 PCT Filed Oct. 19, 1993 PCT Pub. No. WO94/08588 PCT Pub. Date Apr. 28, 1994A pharmaceutical composition containing 7-hydroxylated derivatives of natural st...
|
|
JPH08503473A |
Invented are novel 17 alpha -acyl steroidal 5 alpha -reductase inhibiting compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5- alpha -reductase. Also invented are ...
|
|
JPH08503471A |
Invented are 17 alpha and 17 beta -substituted acyl-3-carboxy-3,5-diene analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5- alpha...
|
|
JPH0826062B2 |
9-Alpha-hydroxy- steroids (I) contg. a D-ring of formula (A) are new; R2 = ethynyl (provided R5 is not acetoxy if R4 = H), haloethynyl, opt. protected OH, cyano, 1'-Ra-ethenyl; or 1',1'-trimethylene dithio-ethyl; Ra = 1-6C alkoxy or alky...
|
|
JPH0859473A |
PURPOSE: To provide a cranial nerve cell protecting agent containing a specific compound as an active component, effective for remarkably suppressing the death of nerve cell induced by glutamic acid, having cranial nerve cell protecting ...
|
|
JPH0816117B2 |
9 alpha, 11 beta and 11 beta-substituted estranes are disclosed which exhibit elevated estrogenic and postcoital contraceptive activities. A process for their manufacture and their use in pharmaceuticals is also disclosed.
|
|
JPH08500821A |
Invented are 17 alpha and 17 beta -alkylketone-3-carboxy aromatic A ring analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5- alph...
|
|
JPH07116215B2 |
Steroid derivatives represented by formula (I) are disclosed. wherein R is a hydrogen atom, a halogen atom, a hydroxy group, or a group -OCOR1, wherein R1 is a linear or branched alkyl group which may be substituted by a halogen atom or ...
|
|
JPH07116222B2 |
A process for preparing 21-desoxyprednisolone 17-esters of formula (IV) is disclosed. The process comprises reacting a prednisolone 17 alpha ,21-cyclic orthoester with an acid in a 40-60% lower alcohol solution to produce a prednisolone ...
|
|
JPH07316186A |
PURPOSE: To obtain a novel nor-bile derivative obtained by bonding plural bile acid groups, having high affinity with a bile acid-transporting system of intestine, capable of inhibiting bile acid absorption and useful as antihyperlipidem...
|
|
JPH07267858A |
PURPOSE: To prepare a pharmaceutical composition containing benzothiophene derivative and progestin, capable of retaining and increasing a bone density, preventing the bone loss and useful for treatment of osteoporosis. CONSTITUTION: Thi...
|
|
JPH0794395B2 |
|
|
JPH0776231B2 |
Novel intermediates useful in the preparation of fluorophenoxyphenoxypropionates and derivatives thereof which possess herbicidal activity selectively in the presence of broadleaf crops.
|
|
JPH0772194B2 |
|
|
JPH0772193B2 |
A novel steroid of the formula I wherein X is methylene and R is an optionally substituted carbocyclic aryl or heterocyclic aryl or optionally substituted vinyl or ethynyl or X is a simple bond or -S- and R is optionally substituted carb...
|
|
JPH07506363A |
PCT No. PCT/US93/03778 Sec. 371 Date Oct. 28, 1994 Sec. 102(e) Date Oct. 28, 1994 PCT Filed Apr. 22, 1993 PCT Pub. No. WO93/22333 PCT Pub. Date Nov. 11, 1993Invented are 17 alpha and 17 beta -substituted acyl-3-carboxy aromatic A ring an...
|
|
JPH0755959B2 |
17 alpha -bromo- alpha and 17 alpha -iodo-vinyl-estrane derivatives of general formula I (I) wherein X is a bromine or iodine atom in Z or E position, R1 is hydrogen, hydroxy or acyloxy with up to 3 C atoms, R2 is hydrogen, alkyl with up...
|
|
JPH0753750B2 |
The invention provides novel pregnane derivatives having the formula: wherein X = F, Cl or Br; R1 = F or Cl; R2 = H( beta OH) or O; R3 = alkyl(1-4 C); R4 = alkyl(1-4 C); and the dotted line indicates the optional presence of a double bon...
|
|
JPH0745511B2 |
Compounds of formula (I) : in which, inter alia, R<1> is H or C1-8alkyl and M is O or S, processes for their preparation, pharmaceutical compositions containing then and their use as inhibitors of 5- alpha -reductase in the treatment in ...
|
|
JPH07503466A |
PCT No. PCT/US93/00211 Sec. 371 Date Jul. 25, 1994 Sec. 102(e) Date Jul. 25, 1994 PCT Filed Jan. 26, 1993 PCT Pub. No. WO93/15103 PCT Pub. Date Aug. 5, 1993.Novel steroids having a 9 alpha -hydroxy or a 9 alpha -carbonate substituent can...
|
|
JPH0710877B2 |
Known pregnane derivatives are prepared by esterificiation of known androstane derivatives to give new ester of Formula III (III) wherein in each case symbolizes a single bond or a double bond, n is 1 or 2, R1 is hydrogen or methyl, R2 i...
|
|
JPH0733719A |
PURPOSE: To provide a novel compound which, when administered to warm- blooded animals, induces a bio-affecting response characteristic of the original acid from which the compound is derived and is less irritating and more excellent in ...
|
|
JPH075629B2 |
The invention relates to novel DELTA <1><4>-16 alpha ,17-dihydroxy-pregnane-16,17-cyclic aldehyde acetal and -cyclic ketone ketal derivatives of general formula (I), wherein A stands for hydrogen or hydroxyl group; X stands for hydrogen ...
|
|
JPH07500086A |
(57) [Summary] Since this publication is application data before electronic filing, summary data is not recorded.
|
|
JPH07500119A |
This invention refers to compounds of formula (I) or double bonds; R is hydrogen or C1-C4 alkyl; R1 is hydrogen or an acyl group; R2 is hydrogen; C1-C4 alkyl unsubstituted or substituted by phenyl; phenyl unsubstituted or substituted by ...
|
|
JPH06316581A |
PURPOSE: To efficiently silylate hydroxyl group without damaging other coexisting functional groups and using an expensive catalyst by reacting a hydroxyl group-containing compound with a silylating agent having Si-N bond in the presence...
|
|
JPH0689021B2 |
Perchloryl fluoride when reacted with the appropriately protected 9 alpha -hydroxyandrostenedione stereoselectively produces the corresponding 6 beta -fluoro steroid.
|
|
JPH06509108A |
In the field of organic chemistry, and therapeutical chemistry in particular, 6-substituted 19-nor pregnanes are provided which are selected from the group consisting of 6-substituted 3-keto-$g(D)4-19-nor-pregnenes having partial formula...
|
|
JPH06279488A |
PURPOSE: To obtain the subject new compound derivative consisting of a steroid derivative having a specific configuration, excellent in bone mass increasing activity and safety, almost free from side effect and useful as an effective com...
|
|
JPH0676328B2 |
|
|
JPH0660195B2 |
The present disclosure is directed to a process and intermediates for the synthesis of Vitamin D3 metabolites such as 1,25-dihydroxycholecalciferol, 25-hydroxycholecalciferol and 24R,25-dihydroxycholecalciferol from 17-keto steroids via ...
|
|
JPH06505958A |
Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-ammobutyric acid/benzodiazepine r...
|
|
JPH06172378A |
PURPOSE: To provide a new compound having an action to promote the production of nerve growth factor and neurotrophic action and, accordingly, useful as an agent for the amelioration and treatment of Alzheimer's dementia, Parkinson's dis...
|
|
JPH06505232A |
PCT No. PCT/SE92/00055 Sec. 371 Date Aug. 31, 1993 Sec. 102(e) Date Aug. 31, 1993 PCT Filed Jan. 29, 1992 PCT Pub. No. WO92/13872 PCT Pub. Date Aug. 20, 1992Disclosed are the 22R and 22S epimers of compounds of the formula wherein X1 rep...
|
|
JPH0635476B2 |
Oestrane and androstane derivatives of the general formula I in which X is a bromine atom, an iodine atom, a triphenyltin group or a trialkyltin group with 1 to 6 carbon atoms per alkyl radical, Y is two hydrogen atoms or one methylene g...
|
|
JPH0633287B2 |
|
|
JPH0617318B2 |
Organoborane compounds are halogenated by reacting an organoborane with iodinemonochloride, brominemono-chloride or a halide salt in the presence of a mild oxidizing agent.
|
|
JPH0614875B2 |
|
